Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program ivps42020-05-13T16:50:34-05:00May 14th, 2020|Press Release| Read More
Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020 ivps42020-05-04T15:22:00-05:00May 5th, 2020|Press Release| Read More
Achieve Life Sciences Announces Private Placement of $1.9 Million ivps42020-04-30T15:51:08-05:00April 30th, 2020|Press Release| Read More
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program ivps42020-03-11T16:19:12-05:00March 13th, 2020|Press Release| Read More
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting ivps42020-03-11T12:52:47-05:00March 12th, 2020|Press Release| Read More
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020 ivps42020-03-02T16:11:51-05:00March 3rd, 2020|Press Release| Read More
Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users ivps42020-02-05T14:45:03-05:00February 6th, 2020|Press Release| Read More
Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery ivps42020-01-13T12:17:22-05:00January 13th, 2020|Press Release| Read More
Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option ivps42019-12-19T13:49:43-05:00December 19th, 2019|Press Release| Read More
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering ivps42019-12-17T13:12:17-05:00December 17th, 2019|Press Release| Read More